1. Home
  2. BEAT vs PDSB Comparison

BEAT vs PDSB Comparison

Compare BEAT & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heartbeam Inc.

BEAT

Heartbeam Inc.

HOLD

Current Price

$0.76

Market Cap

53.2M

Sector

Technology

ML Signal

HOLD

Logo PDS Biotechnology Corporation

PDSB

PDS Biotechnology Corporation

HOLD

Current Price

$0.96

Market Cap

62.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAT
PDSB
Founded
2015
2005
Country
United States
United States
Employees
16
10
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.2M
62.0M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
BEAT
PDSB
Price
$0.76
$0.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
2
Target Price
$5.63
$9.00
AVG Volume (30 Days)
549.3K
966.8K
Earning Date
05-08-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.16
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$315.97
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$0.51
52 Week High
$4.00
$1.66

Technical Indicators

Market Signals
Indicator
BEAT
PDSB
Relative Strength Index (RSI) 37.79 43.81
Support Level $0.54 $0.91
Resistance Level $0.94 $1.12
Average True Range (ATR) 0.06 0.12
MACD -0.01 -0.02
Stochastic Oscillator 24.41 23.24

Price Performance

Historical Comparison
BEAT
PDSB

About BEAT Heartbeam Inc.

HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.

About PDSB PDS Biotechnology Corporation

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.

Share on Social Networks: